СИСТЕМА ГЕМОСТАЗА И АСПИРИНОРЕЗИСТЕНТНОСТЬ ПРИ ПРОГРЕССИРУЮЩЕМ АТЕРОСКЛЕРОЗЕ МАГИСТРАЛЬНЫХ АРТЕРИЙ ГОЛОВЫ

Introduction. Atherosclerosis progression in the internal carotid artery (ICA) is often accompanied by the development of acute cerebral episodes and associated with refractory worsening of hemorheological and hemostasiological parameters despite the regular antiaggregant medication. Aim: to estimate the role of some hemorheological and hemostasiological parameters in the progression of carotid atherosclerosis and development of aspirin resistance taking into account the pharmacokinetics of salicylic and acetylsalicylic acid (ASA) at patients with atherosclerosis under continuous administration of ASA drugs. Materials and methods. We examined 93 patients with ICA atherosclerotic lesion and 50 healthy volunteers. Patient’s examination was carried out before treatment onset and after not less than six months of regular treatment (ASA drugs at dose 100 mg/day). Average follow-up period was 10,1]±]3,5 months.  Results. Identification of predisposition for increased thrombus formation in patients with cerebral atherosclerosis has an important prognostic value in drugs selection aimed at reducing blood thrombogenic potential and achieving of stable antithrombotic effect. Conclusion. Developed approach that combines monitoring of salicylates content with simultaneous measurement of platelet aggregation is more informative because it gives the clinician the opportunity to personalize aspirin therapy. REFERENCES1. SuslinaZ. A., TanashyanM. M., IonovaV. G.Ischemic stroke: blood, vascular wall, antithrombotic therapy [Ishemicheskij insul’t: krov’, sosudistaya stenka, antitromboticheskaya terapiya]. Moskva: Medicinskaya kniga. 2005: 247 s (in Russ.). 2. PiradovM. A.Antiaggregant therapy in the prevention of recurrentischemic strokes [Antiagregantnaya terapiya v profilaktike povtornyh ishemicheskih insul’tov]. Russkij medicinskij zhurnal. 2003;11 (12): 696–8 (in Russ.).3. SuslinaZ. A., TanashyanM. M., DomashenkoM. A.Antithrombotic therapy of ischemic disorders of cerebral circulation from theperspective of evidence-based medicine [Antitromboticheskaya terapiya ishemicheskih narushenij mozgovogo krovoobrashcheniya s pozicij dokazatel’noj mediciny]. Moskva: MIA. 2009: 224 s (in Russ.).4. BornG. V.R. Quantitative investigation into aggregation of blood platelets. J Physiol. 1962; 162: 67–8.5. Capodanno D., Angiolillo D. J.Platelet monitoring for PCI: which test is the one to choose? Hamostaseologie. 2009; 29 (4): 376–80.6. BokarevI. N., PopovaL. V.To the 125th anniversary of acetylsalicylic acid [K 125-letiyu acetilsalicilovoj kisloty]. Racional’naya farmakoterapiya v kardiologii. 2011; 7 (4): 492–500 (in Russ.).7. HalushkaM. K., HalushkaP. V.Why are some individuals resistant to the cardioprotective effects of aspirin? Circulation. 2002; 105: 1620–2.8. Lordkipanidze M.Advances in monitoring of aspirin therapy. Platelets. 2012; 23 (7): 526–36.9. Tanashyan M. M., Domashenko M. A., Raskurazhev A. A. Aspirin resistance: clinical and molecular genetic evaluation methods [Aspirinorezistentnost’: klinicheskie i molekulyarno-geneticheskie metodiki ocenki]. Annaly klinicheskoj i eksperimental’noj  nevro logii  2016; 10 (1): 41–6 (in Russ.).10. Suslina Z. A., Tanashyan M. M., DomashenkoM. A. The problem of resistance to antiplatelet agents in patients with cerebrovascular diseases [Problema rezistentnosti k antiagregantnym preparatam u pacientov s cerebrovaskulyarnymi zabolevaniyami]. Vestnik Rossijskoj Akademii medicinskih nauk. 2011; 7: 3–8 (in Russ.).11. TopolE. J., Gum P., Kottke-Marchant K.Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease (Reply). J Am Coll Cardiol. 2003; 42: 1336–7.12. TanashyanM. M., KhamidovaZ. M., IonovaV. G. et al. A method for detecting resistance to antiplatelet agents in patients with progressive cerebral atherosclerosis [Sposob vyyavleniya rezistentnosti k antiagregantnym preparatam u bol’nyh s progressiruyushchim cerebral’nym ateroslerozom]. Patent RF № 2478965. URL.13. Guyatt G. H., Akl E. A., Crowther M. et al. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel Executive summary: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 41 (2 Suppl): 7S-47S.14. Reference book Vidal 2013. Medicinal drugs in Russia [Spravochnik Vidal’ 2013. Lekarstvennye preparaty v Rossii]. Izd-vo ZAO «YuBM Medika Rus». URL (in Russ.).15. EikelboomJ. W., Hirsh J., WeitzJ. I. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002; 105: 1650–5.16. Macchi L., Christiaens L., Brabant S. et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002; 107: 45–9.17. GrotemeyerK. H., ScharafinskiH. W., HusstedtI. W.Two-year follow-up of aspirin responder and aspirin nоn responder. A pilotstudy including 180 post-stroke patients. Thromb. Res. 1993; 71: 397–403.18. Macchi L., Sorel N., Christiaens L.Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des. 2006; 12 (2): 251–8.19. Grundmann K., Jaschonek K., Kleine B. et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003; 250: 63–6.20. Grosser T., Fries S., LawsonJ. A. et al. Drug resistance and pseudoresistance. An unintended consequence of enteric coating aspirin. Circulation. 2013; 127: 377–85.21. Patrono С., Garcia RodriguezL. A., Landolfi R., Baigent C.Lowdose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353 (22): 2373–83.22. AntonovaK. V., MedvedevR. B., ShabalinaA. A. et al. Violations of carbohydrate metabolism and cerebral atherosclerosis in patients with ischemic impairment of cerebral circulation [Narusheniya uglevodnogo obmena i cerebral’nyj ateroskleroz u bol’nyh s ishemicheskimi narusheniyami mozgovogo krovoobrashcheniya]. Annaly klinicheskoj i eksperimental’noj nevrologii. 2016; 10 (1): 20–6 (in Russ.).23. MasonP. J., Freedman J. E., JacobsA. K.Aspirin resistance: current concepts. Rev Cardiovasc Med. 2004; 5 (3): 156–163.24. AbaimovD. A., SarievA. K., TanashyanM. M. et al. A method for the quantitative determination of salicylates in blood plasma [Sposob kolichestvennogo opredeleniya salicilatov v plazme krovi]. Patent na izobretenie № 2622996 ot 21.06.17. URL.